Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible

Lung cancer is the leading cause of cancer death in the United States with a five-year survival of 16.8% for all stages and median survival of four months for Stage IV disease. We report a case of a 54-year-old male with a seven-year survival after being diagnosed with Stage IV epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Kedia, Shiksha, Garcia, Gwenalyn, Dhar, Meekoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725754/
https://www.ncbi.nlm.nih.gov/pubmed/26835190
http://dx.doi.org/10.7759/cureus.419
_version_ 1782411678493704192
author Kedia, Shiksha
Garcia, Gwenalyn
Dhar, Meekoo
author_facet Kedia, Shiksha
Garcia, Gwenalyn
Dhar, Meekoo
author_sort Kedia, Shiksha
collection PubMed
description Lung cancer is the leading cause of cancer death in the United States with a five-year survival of 16.8% for all stages and median survival of four months for Stage IV disease. We report a case of a 54-year-old male with a seven-year survival after being diagnosed with Stage IV epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative adenocarcinoma of the lung, demonstrating an exceptional response to treatment. 
format Online
Article
Text
id pubmed-4725754
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-47257542016-02-01 Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible Kedia, Shiksha Garcia, Gwenalyn Dhar, Meekoo Cureus Oncology Lung cancer is the leading cause of cancer death in the United States with a five-year survival of 16.8% for all stages and median survival of four months for Stage IV disease. We report a case of a 54-year-old male with a seven-year survival after being diagnosed with Stage IV epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative adenocarcinoma of the lung, demonstrating an exceptional response to treatment.  Cureus 2015-12-19 /pmc/articles/PMC4725754/ /pubmed/26835190 http://dx.doi.org/10.7759/cureus.419 Text en Copyright © 2015, Kedia et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Kedia, Shiksha
Garcia, Gwenalyn
Dhar, Meekoo
Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
title Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
title_full Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
title_fullStr Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
title_full_unstemmed Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
title_short Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
title_sort stage iv egfr mutation-negative and alk mutation-negative lung adenocarcinoma: long-term survival is possible
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725754/
https://www.ncbi.nlm.nih.gov/pubmed/26835190
http://dx.doi.org/10.7759/cureus.419
work_keys_str_mv AT kediashiksha stageivegfrmutationnegativeandalkmutationnegativelungadenocarcinomalongtermsurvivalispossible
AT garciagwenalyn stageivegfrmutationnegativeandalkmutationnegativelungadenocarcinomalongtermsurvivalispossible
AT dharmeekoo stageivegfrmutationnegativeandalkmutationnegativelungadenocarcinomalongtermsurvivalispossible

Ejemplares similares